Serum A-FABP is increased and closely associated with elevated NT-proBNP levels in type 2 diabetic patients treated with rosiglitazone

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Zhou, Mi ^a,b   Bao, Yuqian ^b   Lu, Junxi ^b   Zhou, Jian ^b   Jia, Weiping ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; FATTY ACID BINDING PROTEIN 4; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BRAIN NATRIURETIC PEPTIDE; FATTY ACID BINDING PROTEIN; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE INSULIN RESPONSE; ADULT; AGE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE ESCALATION; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN RESPONSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; SIGNAL TRANSDUCTION;

ADULT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RECEPTOR CROSS-TALK; THIAZOLIDINEDIONES;

EID: 80055027968     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027032     Document Type: Article

References (35)

1. Hertzel AV, Bernlohr DA, (2000) The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 11: 175-180.
2. Boord JB, Fazio S, Linton MF, (2002) Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol 13: 141-147.
3. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, et al. (2004) Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 110: 1492-1498.
4. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, et al. (2006) Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 52: 405-413.
5. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, et al. (2007) Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 115: 1537-1543.
6. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, et al. (2007) Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 30: 2667-2672.
7. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, et al. (2001) Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7: 699-705.
8. Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, et al. (2006) A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci U S A 103: 6970-6975.
9. Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, et al. (2010) Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis 211: 164-169.
10. Rhee EJ, Lee WY, Park CY, Oh KW, Kim BJ, et al. (2009) The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol 160: 165-172.
11. Bao Y, Lu Z, Zhou M, Li H, Wang Y, et al. (2011) Serum levels of adipocyte Fatty Acid-binding protein are associated with the severity of coronary artery disease in chinese women. PLoS ONE 6: e19115.
12. Niemeyer NV, Janney LM, (2002) Thiazolidinedione-induced edema. Pharmacotherapy 22: 924-929.
13. Singh S, Loke YK, Furberg CD, (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298: 1189-1195.
14. Pelton PD, Zhou L, Demarest KT, Burris TP, (1999) PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem Biophys Res Commun 261: 456-458.
15. Turkmen Kemal Y, Guvener Demirag N, Yildirir A, Atar A, Dogruk Unal A, et al. (2007) Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus. Acta Diabetol 44: 149-156.
16. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al. (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347: 161-167.
17. de Lemos JA, Hildebrandt P, (2008) Amino-terminal pro-B-type natriuretic peptides: testing in general populations. Am J Cardiol 101: 16-20.
18. Alberti KG, Zimmet PZ, (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553.
19. Wang J, Bao YQ, Hu C, Zhang R, Wang CR, et al. (2008) Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients. Acta Pharmacologica Sinica 29: 252-258.
20. Yu W, Hu C, Zhang R, Wang C, Qin W, et al. (2011) Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. Clin Pharmacol Ther 89: 437-442.
21. Larsson H, Ahren B, (1998) Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine. Diabetologia 41: 772-777.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
23. Perera RJ, Marcusson EG, Koo S, Kang X, Kim Y, et al. (2006) Identification of novel PPARgamma target genes in primary human adipocytes. Gene 369: 90-99.
24. Schachtrup C, Emmler T, Bleck B, Sandqvist A, Spener F, (2004) Functional analysis of peroxisome-proliferator-responsive element motifs in genes of fatty acid-binding proteins. Biochem J 382: 239-245.
25. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, et al. (2007) Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 195: e150-158.
26. Ogawa S, Takeuchi K, Ito S, (2003) Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab 88: 3993-3996.
27. Sambanis C, Tziomalos K, Kountana E, Kakavas N, Zografou I, et al. (2008) Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol 45: 23-30.
28. El-Muayed M, Lavis VR, Safi HJ, Fuentes F, (2004) Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring? Am J Cardiol 93: 600-602.
29. Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, et al. (2009) Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res 105: 326-334.
30. Vural B, Atalar F, Ciftci C, Demirkan A, Susleyici-Duman B, et al. (2008) Presence of fatty-acid-binding protein 4 expression in human epicardial adipose tissue in metabolic syndrome. Cardiovasc Pathol 17: 392-398.
31. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS, (2005) The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. J Biol Chem 280: 12888-12895.
32. Coe NR, Bernlohr DA, (1998) Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim Biophys Acta 1391: 287-306.
33. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, et al. (2004) Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 43: 1590-1595.
34. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, et al. (2005) Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112: 2163-2168.
35. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, et al. (2008) Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 19: 130-137.